# Angelini Ventures

> Angelini Ventures is a VC fund in Rome backing Health Care and Biotechnology. See 32 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Rome, Italy
- Total investments: 32
- Last investment: Jul 2026
- Lead investor: 38%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/angelini-ventures/
- Website: https://www.angeliniventures.com

Angelini Ventures is an investment firm.

## Contacts

5 contacts available for Angelini Ventures. Shizune tracks 5 team members at Angelini Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/angelini-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $3.3M–$13M |
| Series A | $11M–$105M |
| Series B | $19M–$132M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 11 | 34% |
| Biotechnology | 8 | 25% |
| Medical | 7 | 22% |
| Therapeutics | 7 | 22% |
| Medical Device | 4 | 13% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 9 | 28% |
| Series B | 4 | 13% |
| Seed | 3 | 9% |
| Series C | 3 | 9% |
| Pre-Seed | 1 | 3% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 8 | 25% |
| Italy | 2 | 6% |
| Switzerland | 2 | 6% |
| France | 1 | 3% |
| Belgium | 1 | 3% |

10 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Nils Bottler | Principal | 1 | https://shizune.co/investors/profile/nils-bottler |
| Paolo Di Giorgio | Chief Executive Officer & Managing Director | 4 | https://shizune.co/investors/profile/paolo-di-giorgio |
| Regina Hodits | Managing Director | 15 | https://shizune.co/investors/profile/regina-hodits |
| Sarah Fox | Investor | 1 | https://shizune.co/investors/profile/sarah-fox-5abb |
| Sergio Di Condojanni | Chief Executive Officer | 3 | https://shizune.co/investors/profile/sergio-marullo-di-condojanni |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Handspring Health | Handspring is redesigning the family mental healthcare experience from the ground up. Our omnichannel care delivery model tightly integrates different modalities of care, including in-person, digital and devices. Through the use of technology, health plan partnerships, and highly trained clinicians. Handspring Health aims to make quality mentalhealthcare more accessible to all families. | $19M | Series B | Jul 07, 2026 |  |
| Cour Pharmaceuticals Development | Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $50M | Series B | Jun 18, 2026 |  |
| Rosso | Rosso is a startup dedicated to eliminating the blood shortage crisis in Italy by serving as a connective tissue in the blood supply chain, collaborating with schools, universities, donor associations, and hospitals. Our primary goal is to reduce patient wait times by increasing the number of donors, particularly young donors.Currently,Generation Z is not donating blood significantly; the average donor age is 45, while donation is allowed from 18 to 65 years old. Through innovative social media campaigns and a booking platform, we raise awareness among young people, encouraging them to book donations at nearby centers and providing instant chat access with hematologists to address their concerns.For companies, we offer a welfare service and sustainability membership that engages employees in health prevention and blood donation. We organize awareness webinars, donation days, and monitor employee health, providing impact reports. These activities are included in the company's sustainability report and contribute to B-Corp certification.Our third pillar involves management software for hospitals. We offer a plugin that optimizes blood stock management in hospitals by managing donor portfolios and the relationships between donors, associations, and hospitals. By knowing the blood stock levels, we can send automatic recalls or alerts when blood is needed and there are donors nearby ready to donate. With the help of AI, we can predict future blood stock needs, required blood types, and the timing of potential shortages. | $3.5M | Seed | Jun 10, 2026 |  |
| Nuclidium | NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. | $33.6M | Series B | May 28, 2026 |  |
| Hypervision Surgical | Making surgeries more precise, safer and faster. Guiding the future of surgery using AI-powered hyperspectral imaging. | $23M | Series A | Apr 29, 2026 |  |
| Laigo Bio | Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $6.4M | Seed | Mar 23, 2026 |  |
| Laigo Bio | Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $13.4M | Seed | Dec 03, 2025 |  |
| CoMind | CoMind is creating noninvasive neural technological hardware and software to augment the human brain and connect advanced artificial intelligence to the neocortex to help humans compete with the rapid advancement of AI. The neocortex is the area of the brain which is responsible for brain functions such as sensory perception, cognition, generationof motor commands, spatial reasoning, and language and focused on augmenting this area with artificial intelligence using advanced hardware and cutting-edge software. Their non-invasive brain-computer interfaces allow communication with the brain. CoMind’s mission is to create the next computing interface, whilst simultaneously improving our understanding of the human brain and neurological disorders. | $60M | Series A | Oct 20, 2025 |  |
| Adcytherix | Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $122.8M | Series A | Oct 16, 2025 |  |
| Serenis Health | Serenis Health provides video-based psychotherapy, coaching, and psychological support courses. It believes that the internet is critical to increasing access to mental health care. It makes use of data and digital tools to improve the efficacy of therapies. But, unlike other platforms, it is also a medical center, which means it is responsible forcourse quality and must meet the same standards as any polyclinic. | $14.1M | Series A | Sep 29, 2025 |  |

10 of 32 investments shown.

## Co-investors
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 7 deals together
- [Bayern Kapital](https://shizune.co/investors/profile/bayern-kapital) — VC Fund, 4 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 3 deals together
- [ARGOBIO](https://shizune.co/investors/profile/argobio) — VC Fund, 3 deals together
- [Asahi Kasei](https://shizune.co/investors/profile/asahi-kasei) — VC Fund, 3 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [CDP Venture Capital](https://shizune.co/investors/profile/cdp-venture-capital) — VC Fund
- [Club degli Investitori](https://shizune.co/investors/profile/club-degli-investitori) — VC Fund
- [Primo Capital](https://shizune.co/investors/profile/barcamper-ventures) — VC Fund

## Featured in investor lists
- [Health Care VC Funds in Italy](https://shizune.co/investors/health-care-vc-funds-italy)
- [Medical VC Funds in Italy](https://shizune.co/investors/medical-vc-funds-italy)
- [Biotechnology Investors in Italy](https://shizune.co/investors/biotechnology-investors-italy)
- [Biotech Investors in Italy](https://shizune.co/investors/biotech-investors-italy)
- [Biotech VC Funds in Italy](https://shizune.co/investors/biotech-vc-funds-italy)
- [Biotechnology VC Funds in Italy](https://shizune.co/investors/biotechnology-vc-funds-italy)

## FAQ

### What does Angelini Ventures invest in?

Angelini Ventures invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 32 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Angelini Ventures's check size?

Angelini Ventures typically joins rounds of $3.3M–$13M at Seed, $11M–$105M at Series A and $19M–$132M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Angelini Ventures participates in.

### How do I contact Angelini Ventures?

Public channels for Angelini Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Angelini Ventures?

The team at Angelini Ventures includes Nils Bottler (Principal), Paolo Di Giorgio (Chief Executive Officer & Managing Director) and Regina Hodits (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co